Therapeutic Solutions International Spin Off Campbell Neurosciences Creates Saliva Based Test for Suicidal Ideations

Rhea-AI Summary

Therapeutic Solutions International (TSOI) announced that its spin-off, Campbell Neurosciences, successfully validated a saliva-based suicidal ideation predictive test. This follows earlier success with a blood-based biomarker. The trial assessed inflammatory marker levels across three patient groups, showing significant differences in cytokine levels. CEO Kalina O’Connor emphasized the test's convenience for patients, allowing for point-of-care assessment. The CDC states suicide rates are double that of homicides, making this tool potentially impactful. CEO Timothy Dixon highlighted the test's prospects for personalized psychiatric care.

Positive

• Successful validation of saliva-based test for suicidal ideation.
• Significant difference in inflammatory markers between patient groups supports test credibility.
• Potential to improve patient assessment and care in psychiatric settings.

Negative

• None.

Biotech Company Leverages Previous Clinical Trial Blood Based Biomarker Data to Create Point of Care Psychiatric Assessment Tool

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today its Spin Off Company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva based system. Previously the Company reported successful stratification of suicidal tendencies using a proprietary blood-based biomarker.

In the ClinicalTrials.gov registered trial¹, the Company previously assessed levels of the inflammatory marker in 10 patients with no history of suicide (Group 1), 10 patients with suicidal ideations (Group 2), and 10 patients with suicidal ideations who attempted suicide in the last 6 months (Group 3). Results demonstrated that patients in Group 1 had 7.6±2.4 pg/ml of cytokine, whereas Group 2 had 28.9 ±6.3 pg/ml and in Group 3 had 45.8 ±7.7 pg/ml².

“Due to difficulties associated with blood draws that is specific to the target patient population, as well as advantages of performing and obtaining results of the test in the doctor’s office, we have opted to focus on development of a saliva-based point of care test,” said Kalina O’Connor, President, and CEO of Campbell Neurosciences. “Today’s validation of our saliva-based test is the first step towards larger clinical trials and commercialization of the first biological-based system to help predict individuals at risk of this modern-day epidemic.”

According to the US Centers for Disease Control (CDC), there are twice as many deaths from suicide as compared to homicide. Additionally, suicide is the second leading cause of death among individuals between the ages of 10-34.

“The prospects of a simple saliva-based test will allow for a more personalized approach to regenerative psychiatry, which in the end will result in more lives saved,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “In addition to the accomplishment of this significant milestone, we are proud of the patent portfolio being developed by Campbell which discloses regenerative and immunological approaches to mental illness and drug addiction.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Correlation of Campbell Score With Suicidal Ideation - Full Text View - ClinicalTrials.gov

2 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction | BioSpace

View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005399/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International

FAQ

What is the latest announcement from Therapeutic Solutions International (TSOI)?

TSOI announced the validation of a saliva-based test for predicting suicidal ideation through its spin-off, Campbell Neurosciences.

What were the findings of the clinical trial related to TSOI's saliva test?

The trial showed significant differences in cytokine levels among patients with different suicidal ideation histories, validating the saliva-based test.

How does the new saliva test from TSOI compare to the previous blood test?

The saliva test aims to improve patient convenience over the blood test, which posed difficulties in the target population.

What are the implications of TSOI's saliva test for mental health care?

The saliva test could lead to a more personalized approach in psychiatric care, potentially saving lives by improving risk assessment.